香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本公告僅作參考，並非收購、購買或認購本公司證券的邀請或要約。 本公告或其任何副本概不得直接或間接在美國，或在刊發或派發本公告屬違法的 任何其他司法權區內刊發或派發。 本公告並非在美國購買或認購任何證券之要約或招攬，亦不構成其一部分。本公 告所述證券並未且將不會根據《1933年美國證券法》（「美國證券法」）登記，亦不會 在美國提呈或出售，除非根據美國證券法作出登記或獲豁免或為毋須根據美國證 券 法 作 出 登 記 之 交 易 。 本 公 司 無 意 根 據 美 國 證 券 法 登 記 本 公 告 內 所 指 之 任 何 證 券，或在美國進行證券之公開發售。 Akeso, Inc. 康 方 生 物 科 技（ 開 曼 ）有 限 公 司 （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：9926） 根據一般授權配售新股 ...

智通财经APP获悉，8月25日,阿里巴巴-W（09988）、康方生物（09926）、香港交易所（00388）南向 资金净流入金额位列市场前三，分别净流入5.81 亿、5.41 亿、4.34 亿 前10大资金净流入榜 | 股票名称 | 净流入(元)↓ | 净流入比 | 收盘价 | | --- | --- | --- | --- | | 阿里巴巴-W(09988) | 5.81 亿 | 2.88% | 124.500（+5.51%） | | 康方生物(09926) | 5.41 亿 | 25.36% | 169.500（-4.18%） | | 香港交易所(00388) | 4.34 亿 | 8.05% | 462.800（+3.30%） | | 快手-W(01024) | 4.28 亿 | 9.49% | 78.750（+5.14%） | | 地平线机器人-W(09660) | 4.01 亿 | 12.50% | 7.760（+1.31%） | | 中兴通讯(00763) | 3.97 亿 | 11.24% | 37.100（+2.88%） | | 晶泰控股(02228) | 3.95 亿 | 12.26% | ...

Summary of Key Points from the Conference Call of 康方生物 Company Overview - 康方生物 is advancing in the field of tumor immunotherapy, entering the 2.0 era with products like 卡度尼利 and 伊沃西, while actively exploring the ADC sector and various combination therapies [2][6][8]. Financial Performance - In the first half of 2025, 康方生物 achieved a total revenue of 14.1 billion RMB, with a commercial sales increase of 49% year-on-year [3][49]. - The gross profit from commercial sales was 11.1 billion RMB, a 20% increase from 8.89 billion RMB in the same period last year [50]. - R&D expenses rose by 23% to 7.3 billion RMB, while cash reserves stood at 71.38 billion RMB [50][13]. Clinical and Commercial Achievements - Significant clinical results were reported for AK112, which showed positive overall survival (OS) in EGFR TKI-resistant indications, marking it as the first IO drug to achieve such results globally [4][11]. - Multiple phase III clinical trials for 卡度尼利 have been initiated, covering various cancers including lung, gastric, liver, and cervical cancers [4][5]. - The final analysis of 伊沃西 (Harmony A) demonstrated statistically significant OS results, reinforcing its market position [2][4]. Product Pipeline and Development - 康方生物 has several products in the pipeline, with multiple autoimmune products expected to be approved between late 2024 and early 2025 [2][4]. - The company is focusing on ADC development, with two dual-target ADC products entering clinical stages [4][10]. - The company has independently conducted international multi-center clinical trials for 派安普利, showcasing its capabilities in global registration systems [2][10]. Strategic Direction - 康方生物 aims to enhance its product offerings in tumor immunotherapy and ADC, with plans to combine PD-1 with ADC to improve efficacy and reduce toxicity [6][8]. - The company is expanding its international presence, with clinical data showing consistency between Chinese and global data, indicating the potential for global patient treatment [7][8]. Market Position and Future Outlook - The company has established a strong commercial presence, with its dual antibody products included in the national medical insurance directory, covering over 2,000 hospitals [11][20]. - Future plans include expanding the market for non-tumor drugs and enhancing the commercialization of existing products like AK112 and AK104 [9][20]. - 康方生物 is committed to maintaining a balance between R&D investment and commercial operations, aiming to reduce R&D expenses as a percentage of sales over time [63][62]. Challenges and Considerations - The company reported a loss of 588 million RMB in the first half of 2025, attributed to increased R&D investments and equity investment losses [52][53]. - 毛利率 (gross margin) has decreased due to price adjustments following the inclusion of key products in medical insurance [61][62]. Conclusion - 康方生物 is positioned for significant growth in the biopharmaceutical sector, with a robust pipeline and strategic focus on innovative therapies, while navigating challenges related to financial performance and market dynamics [2][4][8].

Core Viewpoint - Kangfang Biopharma reported a revenue of 1.412 billion yuan for the first half of 2025, marking a year-on-year increase of 37.75%, while the loss expanded to 588 million yuan from 249 million yuan in the same period last year [1][3] Financial Performance - Revenue for the period was 1.412 billion yuan, a 37.75% increase year-on-year [1] - Commercial sales revenue reached 1.402 billion yuan, up 49.20% year-on-year [1] - The company incurred a loss of 588 million yuan, which is an increase from the previous year's loss of 249 million yuan [1][3] Revenue Drivers - The growth in commercial sales revenue was primarily driven by the inclusion of AK104 and AK112 in the national medical insurance since January, leading to increased sales volume [1] - The increase in losses was attributed to a rise in equity investment losses from a partnership with Summit, which increased from 32.6 million yuan to 192 million yuan, as well as higher R&D expenses and stock incentive costs [3] Product Pipeline and Market Position - Kangfang Biopharma has received approval for seven products, including AK104 and AK112, which are key dual antibodies, and has expanded its commercial product range to include metabolic and autoimmune areas [4] - The sales team has grown from over 800 to 1,200 members, covering oncology and specialty drug sectors [4] - The company is focusing on AK112, which has shown promising results in clinical trials for non-small cell lung cancer [5][8] Clinical Development and Strategy - AK112 has achieved significant clinical endpoints in trials, including a statistically significant improvement in progression-free survival (PFS) [8][9] - The company is pursuing a strategy termed "IO2.0+ADC2.0," which aims to integrate dual antibodies with antibody-drug conjugates (ADCs) [12][13] - Kangfang Biopharma's pipeline includes ongoing clinical trials for various indications, with a focus on enhancing the efficacy of existing treatments [12][16]

智通财经8月27日讯（编辑 冯轶）据Wind数据显示，南向资金今日成交约1911.72亿港元，较前一日再度放量近430亿；约为今日恒指成交总额的51.48%，占 比重回5成以上但处于短线较低水平。 值得关注的是，港股今日放量下行，南向资金再度逆势大举加仓，全天净买入约153.71亿港元。其中，沪港股通净流入约90.05亿港元，深港股通 净流入约63.66亿港元。 值得关注的是，盈富基金(02800.HK)、恒生中国企业(02828.HK)、南方恒生科技(03033.HK)三大ETF分别获资金扫货55.49亿、30.43亿、9.53亿港元。 个股方面，交易所数据显示，今日南向资金 大幅净买入：阿里巴巴-W(09988.HK)21.78亿港元；美团-W(03690.HK)17.82亿港元；康方生物(09926.HK)5.74亿港元。 大幅净流出：中芯国际(00981.HK)6.59亿港元；小米集团-W(01810.HK)2.97亿港元。 投资要点 阿里巴巴-W今日涨0.16%，短线资金趋势不明，前5日减持154万股。 美团-W今日跌3.08%，短线资金加速流入，前5日加仓2410万股。 康方生物今日跌7.10%， ...

智通财经APP获悉，8月27日港股市场，北水成交净买入153.71亿港元，其中港股通(沪)成交净买入90.05亿港元，港股通(深) 成交净买入63.66亿港元。 北水净买入最多的个股是盈富基金(02800)、恒生中国企业(02828)、阿里巴巴-W(09988)。北水净卖出最多的个股是中芯国际 (00981)、小米集团-W(01810)。 | 股票名称 | 买入额 | 卖出额 | 买卖总额 | | --- | --- | --- | --- | | | | | 净流入 | | 中芯国际 | 31.06亿 | 36.93 乙 | 67.99 亿 | | HK 00981 | | | -5.86 Z | | 阿里巴巴-W | 27.47 乙 | 16.12 Z | 43.60亿 | | HK 09988 | | | +11.35 亿 | | 腾讯控股 | 20.66亿 | 20.12亿 | 40.78亿 | | HK 00700 | | | +5389.26万 | | 恒生中国 ... | 31.25亿 | 8153.80万 | 32.06亿 | | HK 02828 | | | +30.43 亿 | | 盈富基 ...

Market Overview - The Hong Kong stock market experienced a significant decline, with the Hang Seng Index dropping by 1.27%, closing at 25,201.76, down 323.16 points [1][2] - The Hang Seng Tech Index and the Hang Seng China Enterprises Index also fell by 1.47% and 1.4%, respectively, with the China Enterprises Index barely holding above the 9,000-point mark [1][2] Sector Performance - Major technology stocks saw a downturn, with companies like Kuaishou and Meituan falling over 3%, while JD.com dropped by 2.5% [5][6] - Financial sectors, including banks and insurance stocks, collectively underperformed, contributing to the overall market decline [2][5] - The biopharmaceutical sector faced significant losses, particularly after former President Trump announced plans to impose tariffs on drugs, leading to a broad sell-off in biotech stocks [2][5] Real Estate and Property Management - Property management stocks experienced sharp declines, with companies like Excellence Commercial Services dropping 16% and Country Garden Services falling over 11% [7] - Recent real estate policies in major cities like Beijing and Shanghai are expected to stabilize the market, with analysts optimistic about recovery in core cities [7] Brokerage Firms - Chinese brokerage stocks also fell, with Shenwan Hongyuan down over 6% and other major firms like Dongfang Securities and Huatai Securities declining more than 5% [8] - Despite the downturn, there is optimism regarding the brokerage sector's performance due to increased market activity and potential earnings growth [8] Biopharmaceutical Sector - The biopharmaceutical and innovative drug sectors saw significant declines, with stocks like CanSino Biologics and Innovent Biologics dropping over 7% [9] - Analysts suggest that recent changes in liquidity conditions may support a rebound in the Hong Kong stock market, narrowing the gap with the rapidly rising A-share market [9] Consumer Sector - New consumption concept stocks also faced declines, with companies like Nayuki's Tea and Bubble Mart dropping over 5% [10] - The Chinese Ministry of Commerce plans to introduce policies to boost service consumption, indicating a shift towards a balanced consumption model [10] Apple-Related Stocks - Apple-related stocks performed well, with Lens Technology rising nearly 8% ahead of the upcoming iPhone 17 launch event scheduled for September 9 [3][12] Capital Inflows - Southbound capital saw a net inflow of 15.371 billion HKD, indicating continued interest in Hong Kong stocks from mainland investors [12] Hedge Fund Activity - Recent reports indicate that global hedge funds have increased their bets on Chinese stocks, with significant inflows observed in consumer staples and industrial sectors [14]

Market Overview - The Hong Kong stock market experienced a significant decline in the afternoon, with the Hang Seng Index dropping by 1.27%, losing over 300 points. The Hang Seng China Enterprises Index and the Hang Seng Tech Index fell by 1.4% and 1.47% respectively, with the former barely holding above the 9000-point mark [2] - Major technology stocks, which serve as market indicators, continued to decline in the afternoon. Kuaishou and Meituan fell over 3%, while JD.com dropped by 2.5%. Baidu, NetEase, and Tencent saw declines close to 2%, and Xiaomi fell by 0.56%. Alibaba managed to stay slightly positive [3] Sector Performance - The financial sector, including banks, insurance companies, and Chinese brokerage firms, collectively underperformed, contributing to the overall market decline. The performance of individual stocks continued to be affected by ongoing earnings reports, with property management and real estate stocks experiencing significant drops [3] - Biopharmaceutical stocks faced a collective downturn, particularly in the innovative drug sector, following comments from Trump regarding the rapid imposition of tariffs on pharmaceuticals. This led to notable declines in various biopharma stocks [3] Specific Stock Movements - Several biopharmaceutical companies saw substantial declines, including Kanghao Ya-B (-8.59%), Qiansirui Biotechnology (-7.42%), and Kangfang Biotechnology (-7.10%). Other notable decliners included Xiansheng Pharmaceutical (-6.79%) and Shiyao Group (-6.36%) [3] - In contrast, the rare earth sector remained strong, benefiting from the implementation of supply reforms and multiple catalysts. Apple’s upcoming event on September 9, where the iPhone 17 series is expected to be launched, led to a rise in Apple-related stocks, with Lens Technology (300433) surging nearly 8% and reaching a new high since its listing [4]

Core Insights - 康方生物 has achieved significant revenue growth in the first half of 2025, with total revenue reaching 14.12 billion yuan, a year-on-year increase of 37.75% [1] - The company's commercial sales revenue amounted to 14.02 billion yuan, reflecting a 49.20% year-on-year growth, indicating a shift from reliance on licensing income to self-driven commercialization [1] - The approval of key products for major indications has contributed to this growth, enhancing the sustainability of the company's revenue structure [1] Financial Performance - 康方生物 reported a loss of 5.88 billion yuan in the first half of 2025, an increase from a loss of 2.49 billion yuan in the same period last year [2] - The increase in losses is attributed to a rise in R&D expenses, which reached 7.31 billion yuan, a 23.02% year-on-year increase, and a 1.92 billion yuan investment loss from holding shares in Summit Therapeutics [2] Clinical Developments - The company has made significant progress in clinical trials, with the依沃西 drug achieving positive results in international Phase III trials, demonstrating strong clinical efficacy [3] - The dual antibody therapies are positioned as a strategic focus for leading pharmaceutical companies, marking a transition from the "single antibody era" to the "dual antibody era" in cancer treatment [4] Industry Trends - The global PD-(L)1 market is projected to grow from 39.55 billion USD in 2023 to 64.1 billion USD by 2030, with a declining compound annual growth rate, prompting companies to seek differentiation through innovative therapies [3] - The dual antibody sector is becoming a key area for both domestic and international pharmaceutical companies, emphasizing the importance of clinical value, production capability, and commercialization strategies for success [4]

（原标题：中金：维持康方生物(09926)跑赢行业评级 上调目标价至225.00港元） 智通财经APP获悉，中金发布研报称，维持康方生物(09926)2025年和2026年盈利预测不变。维持跑赢行业评级，该行上调AK112临床成功率并将 Summit AK112再授权预期打入估值，根据DCF模型，该行上调目标价87.5%至225.00港币(33.1%上行空间)。公司公布1H25业绩：收入14.12亿元， 同比增长37.75%，业绩符合该行预期。 HARMONi-A最终分析显示OS取得统计学意义 2025年8月，公司宣布AK112联合化疗用于治疗2L EGFRm NSCLC的HARMONi-A临床公布最终数据，取得具有临床意义和统计学显著的OS获 益，公司未来将在学术大会上公布详细数据。该临床结果上一次更新是2024年5月，OS HR为0.80，成熟度为52%，该行认为该结果进一步证明了 AK112在2L EGFRm NSCLC能够为患者带来明显的生存获益。值得注意的是，目前在2L EGFRm NSCLC尚无上市药物取得OS统计学显著性，IO 代表性药物Keytruda、Opdivo、Tecentriq、Ami ...